Q2 FY2026 EarningsQ2 FY2026 results showed a significant beat on the bottom line, with Diluted EPS (GAAP) of -$1.18 vs. the -$1.355 consensus, driven by lower-than-expected operating expenses and higher interest income. Revenue remains at zero as expected for this clinical-stage biotech. The company completed enrollment for its TX45 Phase 2 trial and maintains a strong cash position of $227.1M, extending its runway into Q1 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Tectonic Therapeutic(TECX) predict that the EBIT is -24.22 M (-8.45%), Beat estimate;the EPS is -1.18 (-10.28%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.02B8.45%
-0.03B22.01%
+0.00B13.56%
EPSExceed expectations
-1.1810.28%
-1.35526.64%
+0.175016.36%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf